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ABSTRAK
Latar belakang: Rekomendasi terapi untuk resistensi insulin adalah metformin dan thiazolidindion. Efek samping udem 
perifer akibat thiazolidindion terjadi sebanyak 2-5% dan meningkat menjadi 5-15% bila dikombinasi dengan terapi insulin. 
Telmisartan termasuk angiotensin receptor blocker yang mempunyai efek anti hipertensi sekaligus memperbaiki resistensi 
insulin. Telmisartan berefek agonis terhadap peroxisome proliferator activated receptor γ dan mempunyai struktur yang sama 
dengan pioglitazon dari golongan thiazolidindion. Tujuan penelitian ini adalah mengetahui efek pemberian metformin dan 
telmisartan terhadap resistensi insulin pada pasien sindrom metabolik dengan terapi insulin.
Metode penelitian: Penelitian ini menggunakan before-after design. Penelitian dilakukan di poliklinik penyakit dalam sub 
bagian endokrinologi RSUP Dr. Sardjito Yogyakarta. Subyek penelitian adalah pasien yang memenuhi diagnosis sindroma 
metabolic berdasar IDF 2005, hipertensi dan mendapat terapi insulin. Subyek diberikan terapi metformin dan telmisartan 
selama 12 minggu. Subyek diperiksa HOMA IR sebelum dan sesudah terapi. Rata-rata penurunan HOMA IR diuji 
dengan paired t-test atau tes Wilcoxon. Kemaknaan p <0.05 dianggap signifi kan.
Hasil penelitian: jumlah sampel penelitian sebanyak 27 subyek. Analisis data dilakukan terhadap 11 subyek. Kadar 
glukosa darah puasa mengalami penurunan bermakna setelah terapi (p<0.001) namun kadar insulin puasa mengalami 
kenaikan. HOMA IR mengalami penurunan setelah terapi {p = 0.004 (5.79 –20.26), IK 95%}.
Kesimpulan: terdapat penurunan resistensi insulin yang bermakna secara statistic pada pasien sindrom metabolik dengan 
terapi insulin yang mendapat metformin dan telmisartan.
Kata kunci: sindrom metabolik, terapi insulin, metformin, telmisartan, HOMA IR
ABSTRACT
Background: Recommendations for therapy insulin resistance are metformin and thiazolidindion. Side 
effects of  thiazolidindion due to peripheral edema occurs to 2-5% and increased 5-15% when combined 
with insulin therapy. Telmisartan, an angiotensin receptor blocker, has anti-hypertensive effects and improve 
insulin resistance. Telmisartan effect on peroxisome proliferator activated receptor γ agonist and has the same 
structure of  the group thiazolidindion, pioglitazone. The research objective was to determine the effects 
of  telmisartan and metformin on insulin resistance in metabolic syndrome patients with insulin therapy.
Methods: This study used a before-after design. The study was conducted in the internal medicine clinic of  the 
endocrinology department of  Dr. Sardjito Hospital Yogyakarta. Subjects were patients who met the diagnosis of  
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BACKGROUND
Metabolic syndrome is defi ned as a group 
of  specifi c clinical conditions including visceral 
obesity, hyperglycemia, dyslipidemia and high 
blood pressure. Constituent factors of  the 
metabolic syndrome is a signifi cant risk factor 
for development of  cardiovascular disease 
and type 2 diabetes mellitus (DM).1 Insulin 
resistance and central obesity is thought to be 
the basis of  the underlying pathogenesis of  
the metabolic syndrome.2
Treatment of  metabolic syndrome 
based on the IDF 2005 include lifestyle 
modification and therapeutic intervention 
to improve all components of  the metabolic 
syndrome. Recommendations of  therapy for 
insulin resistance component are metformin 
and thiazolidindion class. Both are proven 
to prevent the development of  pre-diabetes 
individuals to type 2 diabetes.2  Thiazolidindion 
group is limited its use due to side effects 
of  fl uid retention, edema and weight gain.3 
Incidence of  peripheral edema due to 
monotherapy with thiazolidindion is  2-5% 
and increased to 5-15% when combined with 
insulin therapy.4
Hypertension is a common component 
that accompanies metabolic syndrome. 
Telmisartan, an angiotensin receptor blockers 
(ARB) class has the same structure of  the group 
thiazolidindion, pioglitazone. Telmisartan is 
an agonist of  the peroxisome proliferator 
activated receptor γ (PPAR γ) used for the 
treatment of  type 2 diabetes mellitus.1
Hyperinsulinemic euglycemic glucose 
clamp technique is the gold standard tool to 
measure insulin sensitivity.5 HOMA IR is a simple 
mathematical calculation and is not invasive 
and have been approved to measure insulin 
resistance.5 Research declared HOMA IR value 
of  3.875 in patients with DM had a sensitivity 
and specifi city of  49.7% and 69.6%, while the 
limit value of  4.325 at 45.4% and 69%.6
Research on the effects of  telmisartan in 
hypertension has been done but has not been 
performed in patients with metabolic syndrome 
with insulin therapy. The research objective 
was to determine the effects of  telmisartan on 
metformin and insulin resistance in metabolic 
syndrome patients with insulin therapy.
METHODS
The study design was a before-after 
design. The study was conducted in the internal 
medicine department of  endocrinology Dr. 
Sardjito Hospital Yogyakarta. The study began 
in October 2012 until January 2013. Inclusion 
criteria were all patients in the internal medicine 
department of  endocrinology ≥35-65 years 
old, met the diagnosis of  metabolic syndrome 
based on the IDF 2005, hypertension, on 
metabolic syndrome based on the IDF 2005, hypertension and received insulin therapy. Subjects given metformin 
and telmisartan therapy for 12 weeks. Subjects examined HOMA IR before and after treatment. The average 
decrease in HOMA IR was tested by paired t-test  or  Wilcoxon  test.  P  value <0.05 was  considered  signifi cant. 
Result: The total sample were 27 subjects. Data analysis was performed on 11 subjects. Fasting blood 
glucose before and after treatment was signifi cantly decreased (p<0.001) whereas the fasting insulin levels 
increased. HOMA IR was signifi cantly decreased after treatment {p = 0.004 (5.79 – 20.26), CI 95%}. 
Conclusion: this study found insulin resistance decreased signifi cantly in patients with the metabolic 
syndrome of  insulin therapy who received metformin and telmisartan.
Keywords :  metabolic syndrome,  insulin therapy,  metformin,  telmisartan,  HOMA IR
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insulin therapy, were willing to participate in 
research, and have a number to call. Diagnosis 
of  metabolic syndrome according to IDF 
2005 was abdominal obesity plus any 2 of  
the following 4 criterias: triglyceride levels 
≥150 mg/dL, HDL-C in men <40 mg/dL 
and women <50 mg/dL, blood pressure 
≥130/85 mmHg, fasting blood glucose ≥100 
mg/dL.2 Exclusion criteria were taking drugs 
that affect glucose tolerance such as diuretics 
and α or β blockers, steroids, renal dysfunction 
(serum creatinine >1.5 mg/dL), cardiac 
disorders (unstable angina pectoris, myocardial 
infarction, heart failure) and impaired liver 
function (SGOT and SGPT levels >2 times 
the upper limit of  normal ) and pregnancy.
Data recorded patient characteristics 
including age, gender, medical history, weight, 
height, body mass index, waist circumference, 
hip circumference, blood pressure, and fi ll out the 
questionnaire Beck Depression Inventory (BDI). 
Assessment of  depression using restriction score 
>16. Blood samples were taken at baseline, 
including fasting blood glucose and fasting insulin 
levels to calculate HOMA IR. The formula to 
calculate HOMA IR is7:
22.5
fasting plasma insulin (mU/L) x fasting plasma glucose (mmol/L)
     
405
fasting plasma insulin levels ( U/dL) x fasting plasma glucose (mg/dL)n
Patients given metformin and telmisartan 
treatment for 12 weeks. Metformin dose started 
500 mg and gradually increased every week until a 
maximum dose of  2 grams everyday. Telmisartan 
80 mg was given everyday. Monitoring of  fasting 
blood glucose and blood pressure performed 
every 4 weeks. After treatment is completed, 
the patients are taken blood tests and calculate 
HOMA IR. Monitoring the side effects of  therapy 
conducted during the study to complete. Patients 
received an explanation of  the recommended 
diet and physical activity by nutrition experts 
explaining according to Perkeni 2011.
The data were processed using the 
computer program. Characteristics of  the study 
sample shown descriptively. The average decrease 
in HOMA IR before and after treatment were 
tested with paired t-test if  the data were normally 
distributed. The data  were  not  normally 
distributed  will  be  tested  with  Wilcoxon  test. 
Signifi cance p <0.05 was considered signifi cant.
RESULTS
This study was followed by 27 subjects 
to complete the study. Subjects who did not 
comply with treatment instructions were 
excluded from data analysis. There were 4 
people who can not be calculated because 
the value of  HOMA IR was very low fasting 
insulin levels <2 μU/dL. So the amount of  
sample that can be analyzed as many as 11 
people. Subjects consisted of  7 men (63.6 %). 
The subjects had an age range 50-65 years 
with an average age of  57±4.40 years old. 
Characteristics of  the study subjects were 
summarized in table 1.
Table 1. Basic Characteristics of  the 
Study Subjects
Variable N = 11 Total (%)
Mean ± SD
Gender:
- Women 4 (36.4)
- Men 7 (63.6)
Age :
-  ≤ 60 years old 9 (81.8)
-  > 60 years old 2 (18.2)
Body mass index 28.40 ± 3.65
Waist circumference, cm 96.64 ± 8.20
Fasting blood glucose, mg/dL 194.91 ± 57.85
Systolic pressure, mmHg 130.45 ± 12.34
Diastolic pressure, mmHg 84.55± 5.22
Stress 1 (9.1)
Smoke 1 (9.1)
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Table 2. Comparison of  Variables Before and After Treatment
Variable Before (N=11) After (N=11) p
Mean ± SD Mean ± SD
Fasting blood glucose, mg/dL 194.91± 57.85 58.27±58.50 < 0.001 *
Insulin darah puasa, μU/dL 27.59± 19.55 32.01± 22.12 0.688 *
HOMA IR 13.99±11.05 12.84± 10.97 0.004 *
         * paired t – test
The average of  metformin dose was 
1478 mg everyday. Telmisartan dose was 80 
mg everyday. Subjects using a mixture of  
short acting insulin injections and the medium 
as much as 8 subjects (72.7%) and 3 (27.3%) 
using long acting insulin. Average insulin 
dose received at the beginning of  therapy 
was 35.82 units per day while at the end of  
therapy was 29.45 units. At the end of  the 
study was evaluation of  patient adherence to 
recommended dietary food recall way. There 
were 7 (63.6%) subjects who were adherent to 
recommended diet.
Results of  this study HOMA IR scores 
decreased after therapy compared to before 
{ p=0.004 (5.79 to 20.26), 95% confi dence 
interval}. HOMA IR improvement after 
treatment in line with improvements in fasting 
blood glucose (p <0.001) but not in line with 
fasting insulin. Fasting insulin levels increased 
after therapy. Comparison of  variables before 
and after treatment can be seen in table 2.
Dietary variables were analyzed to look 
for effects on HOMA IR. This study get 
no association between dietary adherence 
and decreased HOMA IR (p=0.47). Other 
confounding variables such as stress and 
smoking were not analyzed further because 
the amount was very small.
DISCUSSION
The pathophysiology of  the metabolic 
syndrome are central obesity and insulin 
resistance. Management of  metabolic 
syndrome include lifestyle modifi cation and 
pharmacological therapy. Pharmacological 
therapy on metabolic syndrome is aimed 
at dealing with the excess adipose tissue, 
insulin resistance, dyslipidemia, hypertension, 
prothrombotic and proinflammatory state. 
Therapy to overcome insulin resistance is 
metformin and thiazolidindion.8
Metformin improved insulin resistance 
by lowering fasting blood glucose and 
insulin concentrations. Metformin increases 
in hepatocytes through suppression of  
gluconeogenesis and lowers insulin stimulation 
of  gluconeogenesis by glucagon. Metformin 
increases glucose disposal in non insulin-
dependent diabetes mellitus patients who are 
working in the target muscle. Metformin also 
increases glucose uptake and oxidation in adipose 
tissue as lipogenesis. Metformin increases 
the translocation of  GLUT-1 and GLUT-4 . 
Metformin also lowers the oxidation of  fatty 
acids by 10-20% and will lower blood glucose 
levels through a glucose-fatty acid cycle.9
Angiotensin type 1 receptor (AT1R) 
blockers used in the treatment of  hypertension 
and cardiovascular disease. The study states 
AT1R blockers reduce the risk of  type 2 
diabetes compared to other antihypertensive. 
Animal experiments state that ARBs improve 
insulin resistance by improving the regulation 
of  PPAR γ target gene of  GLUT 4.10 Other 
studies in mice get PPAR γ activity in skeletal 
muscle organs through AMPK/SIRT1.11
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PPAR γ is expressed primarily in adipose 
tissue. PPAR γ plays a role regulating genes 
involved in the differentiation of  adipose, fatty 
acid uptake, storage and glucose uptake. PPAR 
γ stimulates intravascular lipolysis12, has anti 
infl ammatory effects through the inhibition 
of  TNF-α and IL-613, giving the effect of  
anti-oxidation and anti-proliferation in the cell 
walls of  the blood vessels, reducing the risk of  
atherosclerosis.14
The binding of  telmisartan-PPAR γ is 
different with the binding PPAR γ-rosiglitazone 
or pioglitazone. Telmisartan binds only 
partially so as not stimulate PPAR γ in full 
activity. This activity provides the benefi cial 
effect of  providing a safer drug profile in 
preventing fl uid retention, edema and weight 
gain as was the case with the treatment group 
thiazolidindion.3 Telmisartan is an ARB with 
the highest lipophilic nature so most potent to 
induce PPAR γ.10
HOMA IR is a method developed in 
1985 to assess insulin resistance. HOMA IR 
has accuracy comparable to the gold standard 
examination with the glucose clamp, but is 
inferior in terms of  accuracy.6 Results of  
glucose clamp correlated strongly with levels 
of  fasting insulin and HOMA IR.15
In this study, HOMA IR values decreased 
after therapy. This is consistent with the 
hypothesis. HOMA IR improvement on this 
study was supported by improvements in blood 
glucose levels, but not in line with the increase 
in fasting insulin levels. Increase in fasting insulin 
levels can be caused by several factors: genetic 
and not genetic. Research get fasting insulin 
levels were positively correlated with body mass 
index, waist/hip ratio, triglycerides, systolic and 
diastolic blood pressure and inversely with HDL 
cholesterol. However, after adjustment for several 
factors that influence, there is no significant 
association between genetic factors and not with 
fasting insulin levels.16 There is a possibility of  
an increase in fasting insulin levels in this study 
does not refl ect actual conditions. This subjects 
are metabolic syndrome patients receiving 
insulin therapy. Blood insulin were examined 
to calculate HOMA IR and will increase as 
affected exogenous insulin administration.17
Diabetic patients who use insulin therapy 
for a period of  time will be formed in the 
circulating insulin antibodies. Proinsulin to 
insulin injection contained varying amounts can 
stimulate the formation of  antibodies and tie it 
in circulation. In these patients the endogenous 
and exogenous insulin and antibodies will bind to 
obscure the accuracy of  measurement of  insulin 
levels with insulin radioimmunoassay method.18 
Research get diabetic patients in insulin therapy 
increased total fasting insulin in the blood at 
2 months and became stable after 5 months. 
This increase occurred simultaneously with the 
formation of  antibodies.17
Decrease in HOMA IR after metformin 
and telmisartan treatment in this study in line 
with other studies. Derosa et al. indicate the 
telmisartan or irbesartan administration for 
12 weeks in diabetic patients with metabolic 
syndrome who received rosiglitazone can 
improve blood pressure, HOMA IR, HbA1c, 
adiponectin and resistin.19  Vitale et al. show the 
3 month treatment of  telmisartan compared 
with losartan better in fi xing parameters of  
insulin resistance (HOMA IR, HbA1c and 
blood pressure) in hypertensive patients with 
metabolic syndrome.20 Bahadir et al. get a 
different result is the provision of  telmisartan 
or losartan did not improve HOMA IR 
in hypertensive patients with metabolic 
syndrome. Possible causes HOMA IR did not 
experience a signifi cant reduction in this study 
is HOMA IR less than 2.5.1
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This study has the disadvantage that 
the number of  samples analyzed only 11 
subjects. Another weakness of  this study is 
the assessment of  patient compliance based 
solely on interview subjects at the end of  
the study. Drug compliance is not based on a 
count of  the remaining drug is not taken from 
the former drug packs. This led medication 
adherence data become invalid. This study 
can not control confounding variables such 
as excessive dieting, low physical activity, 
stress and smoking so that they can be biased 
towards research.
CONCLUSION
This study found decreased insulin 
resistance signifi cantly in patients with the 
metabolic syndrome of  insulin therapy who 
received metformin and telmisartan.
REFERENCES
1. Bahadir, O., Uzunzulu, M., Oguz, A., 
Bahadir, M.,A. 2007. Effects of  Telmisartan 
and Losartan on Insulin Resistance in 
Hypertensive Patients with Metabolic 
Syndrome. Hypertens Res.; 30: 49–53 
2. IDF, 2006, The Metabolic Syndrome, 
International Diabetes Federation 
3. Kurtz, T.W., 2006, New Treatment 
Strategies for Patients with Hypertension 
and Insulin Resistance, The American Journal 
of  Medicine, Vol 119 (5A): 24S-305 
4. S c h e e n ,  A , J. ,  2 0 0 4  C o m b i n e d 
thiazolidinedione-insulin therapy: should 
we be concerned about safety? Drug saf., 
27(12) : 841-856 
5. Singh, B., Saxena, A., 2010,Surrogate 
markers of  insulin resistance: A review, 
World J Diabetes, 1(2): 36-47 
6. Esteghamati, A., Ashraf, H., Khalilzadeh, 
O., Zandieh, A., Nakhjavani, Z. M., 
Rashidi, A., et al., 2010, Optimal cut-
off  of  homeostasis model assessment 
of  insulin resistance (HOMA IR) for 
the diagnosis of  metabolic syndrome: 
third national surveillance of  risk factors 
of  noncommunicable diseases in Iran. 
Nutrition & Metabolism, 7:26 
7. Qu, H.Q., Li, Q., Rentfro, A.R., Fisher-
Hoch, S.P., McCormick, J.B., 2011, The 
Definition of  Insulin Resistance Using 
HOMA IR for Americans of  Mexican 
Descent Using Machine Learning,PLoS 
ONE, www.plosone.org
8. Cornier, M., Dabelea, D., Hernandez, 
T.L., Lindstrom, R.C., Steig, C. J., Stob, N. 
R., et al. 2008. The Metabolic Syndrome.
Endocrine Reviews; 29(7): 777–822
9. Bailei, C.,J.,Turner, R.,C. 1996. Metformin.
The New England Medical Journal ; 334 : 
574-579
10. Schupp, M., Janke, J., Clasen, R., Unger, 
T., Kintscher, U., 2004,. Angiotensin Type 
1 Receptor Blockers Induce Peroxisome 
Proliferator–Activated Receptor- γ Activity, 
Circulation, 109: 2054-2057 
11. Shiota, A., Shimabukuro, M., Fukuda, 
D., Soeki, T., et al., 2012, Telmisartan 
ameliorates insulin sensitivity by activating 
the AMPK/SIRT1 pathway in skeletal 
muscle of  obese db/db mice, Cardiovascular 
Diabetology, 11:139
12. Yki-Jarvinen, H., 2004, Thiazolidinediones, 
N Engl J Med., 351:1106-1118
Oktariani et al.
14 
13. Fei, J., 2012, PPAR: A Pivotal Regulator 
in Metabolic Syndromes, Endocrinol Metab 
Synd., 1:1-2
14. Yamagishi, S., Nakamura, K., 2006, 
Telmisartan, Its Potential Therapeutic 
Implications in Cardiometabolic Disorders, 
Recent Patents on Cardiovascular Drug Discovery, 
79-83
15. Katsuki, A., Sumida, Y., Gabazza, E.C., 
Murashima, S., Furuta, M., Araki-Sasaki, R., 
2001, Homeostasis Model Assessment Is a 
Reliable Indicator of  Insulin ResistanceDuring 
Follow-up of  Patients With Type 2Diabetes, 
Diabetes Care, 24: 362–365
16. Mayer,  E.J. ,  Newman,  B. ,  Aust in , 
M.A., Zhang, D., Quesenberry, C.P., 
Edwards, K., et al., 1996, Genetic and 
Environmental Influences on Insulin 
Levels  and the Insul in Resistance 
Syndrome: an Analysis of  Women Twins. 
American Journal of  Epidemiology. Vol 143: 
4. 323-32
17. Hedïng, L.G. 1988. Determination of  
Total Serum Insulin (IRI) in Insulin-treated 
Diabetic Patients.Radioimmunoassays for 
Insulin, C-Peptide and Proinsulin : 36-42
18. Kuzuya, H., Blix, P.M., Horwitz, D.L., 
Steiner, D.F., Rubenstein, A.H. 1977. 
Determination of  Free and Total Insulin 
and C-Peptide in Insulin-treated Diabetics. 
Diabetes; 26: 22-29 
19. Derosa, G., Fogari, D’Angelo, A., Cicero, 
A. F.G., Salvadeo, S.A.T., Ragonesi., S.T., 
Ferrari, I., et al. 2007. Metabolic effects of  
telmisartan and irbesartan in type 2diabetic 
patients with metabolic syndrome treated 
withrosiglitazone,Journal of  Clinical Pharmacy 
and Therapeutics; 32: 261–268 
20. Vitale, C., Mercuro, G., Castiglioni, C., 
Cornoldi, A., Tulli, A., Fini, M., et al., 
2005, Metabolic effect of  telmisartan 
and losartan in hypertensivepatients 
with metabolic syndrome, Cardiovascular 
Diabetology, 4: 6 
